French OTC Industry Frustrated By Regulatory Clampdown in 2019
Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.
You may also be interested in...
With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.
Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.
Fears over patient safety will see common OTC drugs including paracetamol moved behind the counter in France from January 2020.